Title

Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression

Authors

Michael W. Smith, National Cancer Institute at Frederick
Michael Dean, National Cancer Institute at Frederick
Mary Carrington, National Cancer Institute at Frederick
Cheryl Winkler, National Cancer Institute at Frederick
Gavin A. Huttley, National Cancer Institute at Frederick
Deborah A. Lomb, National Cancer Institute at Frederick
James J. Goedert, National Cancer Institute at Bethesda
Thomas R. O'Brien, National Cancer Institute at Bethesda
Lisa Jacobson, Johns Hopkins School of Hygiene and Public Health
Richard A. Kaslow, University of Alabama - Birmingham
Susan Buchbinder, San Francisco Department of Public Health
Eric Vittinghoff, San Francisco Department of Public Health
David Vlahov, Johns Hopkins School of Hygiene and Public Health
Keith Hoots, University of Texas Health Science Center at Houston
Margaret Hilgartner, New York Presbyterian Hospital - Cornell Medical Center
Hemophilia Growth and Development Study
Multicenter AIDS Cohort Study
Multicenter Hemophilia Cohort Study
San Francisco City Cohort
ALIVE Study
Stephen J. O'Brien, National Cancer Institute at FrederickFollow

Document Type

Article

Publication Date

8-15-1997

Publication Title

Science

ISSN

0036-8075

Volume

277

Issue/No.

5328

First Page

959

Last Page

965

Abstract

The critical role of chemokine receptors (CCR5 and CXCR4) in human immunodeficiency virus-type 1 (HIV-1) infection and pathogenesis prompted a search for polymorphisms in other chemokine receptor genes that mediate HIV-1 disease progression. A mutation (CCR2-64I) within the first transmembrane region of the CCR2 chemokine and HIV-1 receptor gene is described that occurred at an allele frequency of 10 to 15 percent among Caucasians and African Americans. Genetic association analysis of five acquired immunodeficiency syndrome (AIDS) cohorts (3003 patients) revealed that although CCR2-64I exerts no influence on the incidence of HIV-1 infection, HIV-1-infected individuals carrying the CCR2-64I allele progressed to AIDS 2 to 4 years later than individuals homozygous for the common allele. Because CCR2-64I occurs invariably on a CCR5-+- bearing chromosomal haplotype, the independent effects of CCR5-Δ32 (which also delays AIDS onset) and CCR2-64I were determined. An estimated 38 to 45 percent of AIDS patients whose disease progresses rapidly (less than 3 years until onset of AIDS symptoms after HIV-1 exposure) can be attributed to their CCR2-+/+ or CCR5-+/+ genotype, whereas the survival of 28 to 29 percent of long-term survivors, who avoid AIDS for 16 years or more, can be explained by a mutant genotype for CCR2 or CCR5.

Comments

©1997 American Association for the Advancement of Science

NSUWorks Citation

Smith, Michael W.; Michael Dean; Mary Carrington; Cheryl Winkler; Gavin A. Huttley; Deborah A. Lomb; James J. Goedert; Thomas R. O'Brien; Lisa Jacobson; Richard A. Kaslow; Susan Buchbinder; Eric Vittinghoff; David Vlahov; Keith Hoots; Margaret Hilgartner; Hemophilia Growth and Development Study; Multicenter AIDS Cohort Study; Multicenter Hemophilia Cohort Study; San Francisco City Cohort; ALIVE Study; and Stephen J. O'Brien. 1997. "Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression." Science 277, (5328): 959-965. https://nsuworks.nova.edu/cnso_bio_facarticles/683

ORCID ID

0000-0001-7353-8301

ResearcherID

N-1726-2015